A new trading day began on Friday, with Taysha Gene Therapies Inc (NASDAQ: TSHA) stock price remained unchanged from the previous day of trading, before settling in for the closing price of $1.72. TSHA’s price has ranged from $1.19 to $4.32 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 94.30% over the last five years. Meanwhile, its annual earnings per share averaged -1.44%. With a float of $157.72 million, this company’s outstanding shares have now reached $204.94 million.
The firm has a total of 73 workers. Let’s measure their productivity. In terms of profitability, gross margin is 100.0%, operating margin of -1097.55%, and the pretax margin is -1071.62%.
Taysha Gene Therapies Inc (TSHA) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Taysha Gene Therapies Inc is 23.07%, while institutional ownership is 77.27%. The most recent insider transaction that took place on Jun 27 ’24, was worth 2,999,999. In this transaction 10% Owner of this company bought 1,333,333 shares at a rate of $2.25, taking the stock ownership to the 1,333,333 shares.
Taysha Gene Therapies Inc (TSHA) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.09 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -1.44% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -2.46% during the next five years compared to -63.99% drop over the previous five years of trading.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Trading Performance Indicators
Here are Taysha Gene Therapies Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.41. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 42.33.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.38, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.44 in one year’s time.
Technical Analysis of Taysha Gene Therapies Inc (TSHA)
Analysing the last 5-days average volume posted by the [Taysha Gene Therapies Inc, TSHA], we can find that recorded value of 1.45 million was lower than the volume posted last year of 1.98 million. As of the previous 9 days, the stock’s Stochastic %D was 68.12%. Additionally, its Average True Range was 0.12.
During the past 100 days, Taysha Gene Therapies Inc’s (TSHA) raw stochastic average was set at 25.00%, which indicates a significant decrease from 47.62% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 35.93% in the past 14 days, which was lower than the 105.80% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6592, while its 200-day Moving Average is $2.1525. Now, the first resistance to watch is $1.7687. This is followed by the second major resistance level at $1.8173. The third major resistance level sits at $1.8547. If the price goes on to break the first support level at $1.6827, it is likely to go to the next support level at $1.6453. Should the price break the second support level, the third support level stands at $1.5967.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Key Stats
With a market capitalization of 352.60 million, the company has a total of 205,002K Shares Outstanding. Currently, annual sales are 8,330 K while annual income is -89,300 K. The company’s previous quarter sales were 2,020 K while its latest quarter income was -18,780 K.
